Quantity of eligible patients: CDEC discussed the uncertainty in the number of people with reasonably significant to critical hemophilia B in Canada qualified for etranacogene dezaparvovec. Clinical specialists consulted by CADTH indicated that some patients who will be labeled as acquiring delicate or moderate disease may have a intense bleeding https://hemgenix17273.arwebo.com/58487850/detailed-notes-on-hemgenix